100 Reasons to Invest In Cellmid, page-32

On CX Baldder, progress is slow but progress it is.  Edison updated their research report on the company last week.

http://www.edisoninvestmentresearch.com/research/report/pacific-edge5

" Management expects discussions with the CMS on approval and reimbursement for Cxbladder tests to conclude in mid-2016. CMS, according to Pacific Edge, represents c 40% of its total target market."

I doubt very much if Maria or anyone else can add much  to this .....  except maybe to say that the decisions that follow the discussions will likely happen before CDYO expiry but not much before.  Talk about a close race.  The KP timeframe would be similar IMHO.   These decisions are critical to CDY as they represent a bankable  $2m pa clear royalty stream with no material costs attached.

It's 12 months down the track now so some sort of update on Zoetis would be nice.  There are 2 threads to consider here.  Firstly the "humanised" antibody can be used with existing chemo treatments for dogs as an indicative study .  Secondly, Zoetis like to caninise their mABs and that will take some time.

cheers